ATE413176T1 - Verwendung von 1-azabicyclo(2.2.2)octan-3-on- derivaten zur behandlung von krebstumoren - Google Patents
Verwendung von 1-azabicyclo(2.2.2)octan-3-on- derivaten zur behandlung von krebstumorenInfo
- Publication number
- ATE413176T1 ATE413176T1 AT01970421T AT01970421T ATE413176T1 AT E413176 T1 ATE413176 T1 AT E413176T1 AT 01970421 T AT01970421 T AT 01970421T AT 01970421 T AT01970421 T AT 01970421T AT E413176 T1 ATE413176 T1 AT E413176T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- azabicyclo
- octane
- derivatives
- cancer tumors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical class C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000004568 DNA-binding Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 abstract 1
- 230000007420 reactivation Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23416400P | 2000-09-20 | 2000-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE413176T1 true ATE413176T1 (de) | 2008-11-15 |
Family
ID=22880210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01970421T ATE413176T1 (de) | 2000-09-20 | 2001-09-19 | Verwendung von 1-azabicyclo(2.2.2)octan-3-on- derivaten zur behandlung von krebstumoren |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6921765B2 (de) |
| EP (1) | EP1319000B1 (de) |
| JP (1) | JP4865982B2 (de) |
| AT (1) | ATE413176T1 (de) |
| AU (2) | AU2001290422B2 (de) |
| CA (1) | CA2423192C (de) |
| DE (1) | DE60136473D1 (de) |
| DK (1) | DK1319000T3 (de) |
| ES (1) | ES2316473T3 (de) |
| WO (1) | WO2002024692A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69912808T2 (de) | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel |
| WO2002015906A1 (en) * | 2000-08-21 | 2002-02-28 | Georgetown University | 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon |
| AU2001290422B2 (en) * | 2000-09-20 | 2006-06-15 | Aprea Therapeutics Ab | 1-azabicyclo(2.2.2)octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors |
| WO2003070250A1 (en) * | 2002-02-21 | 2003-08-28 | Aprea Ab | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases |
| JP4516758B2 (ja) | 2002-04-12 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | チロシンキナーゼ阻害剤 |
| DE60316423T2 (de) * | 2002-04-12 | 2008-06-12 | Merck & Co., Inc. | Tyrosinkinase-hemmer |
| EP1496897A4 (de) * | 2002-04-12 | 2006-05-10 | Merck & Co Inc | Tyrosinkinase-hemmer |
| ATE411020T1 (de) * | 2003-03-24 | 2008-10-15 | Aprea Ab | Pharmazeutische verwendung von 1-azabicyclo 2.2.2 octanen und verfahren zum testen von verbindungen auf die fähigkeit zur aktivierung von inaktivem wt p53 |
| SE0300812D0 (sv) * | 2003-03-24 | 2003-03-24 | Karolinska Innovations Ab | Use of chemical compounds for preparing pharmaceutical compositions, and method of testing substances for medical effect |
| SE0400708D0 (sv) * | 2004-03-22 | 2004-03-22 | Aprea Ab | New compounds and use thereof |
| US7790474B1 (en) | 2005-07-15 | 2010-09-07 | Schering Corporation | p53 modulators |
| GB0813873D0 (en) * | 2008-07-30 | 2008-09-03 | Univ Dundee | Compounds |
| CA2769038A1 (en) * | 2009-07-31 | 2011-02-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Antiangiogenic small molecules and methods of use |
| WO2011089234A2 (en) * | 2010-01-21 | 2011-07-28 | Aprea Ab | Method and composition |
| CN104860994A (zh) * | 2014-02-20 | 2015-08-26 | 中国药科大学 | 3-奎宁环酮类含磷化合物的制备及其医药用途 |
| WO2017159877A1 (en) * | 2016-03-18 | 2017-09-21 | Eisai R&D Management Co., Ltd. | Use of eribulin and 3-quinuclidinone derivatives in the treatment of cancer |
| CN109280056A (zh) * | 2017-07-21 | 2019-01-29 | 上海时莱生物技术有限公司 | 手性3-奎宁环酮类化合物、制备方法及用途 |
| CN109280054A (zh) * | 2017-07-21 | 2019-01-29 | 上海时莱生物技术有限公司 | 氘代3-奎宁环酮类化合物、制备方法及用途 |
| US11913077B2 (en) | 2018-03-09 | 2024-02-27 | Texas Tech University System | Compositions and methods for the diagnosis and treatment of ALT cancer |
| US20210371855A1 (en) * | 2018-06-15 | 2021-12-02 | Ideaya Biosciences, Inc. | Methods of inhibiting proliferative cells |
| BR112021005171A2 (pt) | 2018-09-20 | 2021-06-15 | Aprea Therapeutics Ab | derivados de quinuclidina-3-ona e seu uso em tratamento de câncer |
| WO2021053155A1 (en) | 2019-09-18 | 2021-03-25 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein |
| WO2021170772A1 (en) | 2020-02-26 | 2021-09-02 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling |
| WO2021180338A1 (en) | 2020-03-09 | 2021-09-16 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant |
| WO2022175402A1 (en) | 2021-02-18 | 2022-08-25 | Aprea Therapeutics Ab | Quinuclidine-3-one derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3384641A (en) | 1967-09-19 | 1968-05-21 | Aldrich Chem Co Inc | 2-methylene-3-quinuclidones |
| US3726877A (en) * | 1970-10-28 | 1973-04-10 | Univ Temple | Amine substituted methylene quinuclidone anti-bacterial agents |
| US4448906A (en) * | 1982-06-16 | 1984-05-15 | Nuodex Inc. | Surface-coating compositions |
| JPS6028961A (ja) * | 1983-07-25 | 1985-02-14 | 高取 吉太郎 | Ν−１−アダマンチルマレイミド及び其の製法 |
| US4599344A (en) * | 1984-10-31 | 1986-07-08 | Schering A.G. | Quinuclidines and quinuclidinium salts as antiarrhythmic agents |
| JPS6225137A (ja) * | 1985-07-26 | 1987-02-03 | Bridgestone Corp | ゴム組成物 |
| DE69105131T2 (de) * | 1990-06-01 | 1995-03-23 | Pfizer | 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. |
| WO1993021184A1 (en) * | 1992-04-10 | 1993-10-28 | Zeneca Limited | Biphenylylquinuclidine derivatives as squalene synthase inhibitors |
| DK0785198T3 (da) * | 1996-01-19 | 2000-11-13 | Lonza Ag | Fremgangsmåde til fremstilling af optisk aktiv 3-quinuclidinol |
| AU4085797A (en) | 1996-08-23 | 1998-03-06 | First Chemical Corporation | Polymerization processes using aliphatic maleimides |
| US6432975B1 (en) * | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| AU2001290422B2 (en) * | 2000-09-20 | 2006-06-15 | Aprea Therapeutics Ab | 1-azabicyclo(2.2.2)octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors |
-
2001
- 2001-09-19 AU AU2001290422A patent/AU2001290422B2/en not_active Expired
- 2001-09-19 JP JP2002529102A patent/JP4865982B2/ja not_active Expired - Lifetime
- 2001-09-19 DK DK01970421T patent/DK1319000T3/da active
- 2001-09-19 EP EP01970421A patent/EP1319000B1/de not_active Expired - Lifetime
- 2001-09-19 AU AU9042201A patent/AU9042201A/xx active Pending
- 2001-09-19 US US10/381,011 patent/US6921765B2/en not_active Expired - Lifetime
- 2001-09-19 WO PCT/SE2001/002008 patent/WO2002024692A1/en not_active Ceased
- 2001-09-19 AT AT01970421T patent/ATE413176T1/de active
- 2001-09-19 CA CA2423192A patent/CA2423192C/en not_active Expired - Lifetime
- 2001-09-19 ES ES01970421T patent/ES2316473T3/es not_active Expired - Lifetime
- 2001-09-19 DE DE60136473T patent/DE60136473D1/de not_active Expired - Lifetime
-
2004
- 2004-12-14 US US11/010,430 patent/US7348330B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20050090540A1 (en) | 2005-04-28 |
| EP1319000A1 (de) | 2003-06-18 |
| AU2001290422B2 (en) | 2006-06-15 |
| US7348330B2 (en) | 2008-03-25 |
| DK1319000T3 (da) | 2009-02-16 |
| WO2002024692A1 (en) | 2002-03-28 |
| CA2423192A1 (en) | 2002-03-28 |
| CA2423192C (en) | 2010-11-23 |
| DE60136473D1 (de) | 2008-12-18 |
| JP2004509890A (ja) | 2004-04-02 |
| AU9042201A (en) | 2002-04-02 |
| US6921765B2 (en) | 2005-07-26 |
| ES2316473T3 (es) | 2009-04-16 |
| US20030166674A1 (en) | 2003-09-04 |
| JP4865982B2 (ja) | 2012-02-01 |
| WO2002024692A8 (en) | 2002-09-26 |
| EP1319000B1 (de) | 2008-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE413176T1 (de) | Verwendung von 1-azabicyclo(2.2.2)octan-3-on- derivaten zur behandlung von krebstumoren | |
| ATE265456T1 (de) | 2-amino-6-anilino-purine und deren verwendung als arzneimittel | |
| ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| DE60105295D1 (de) | Chinazolinderivate zur behandlung von tumoren | |
| ATE282413T1 (de) | Verwendung von tempol zur behandlung von essentiellem hochdruck | |
| ATE422358T1 (de) | Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen | |
| ATE468137T1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
| TR200001203T2 (tr) | Yeni birleşik maddeler | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE453653T1 (de) | Platinkomplexe zur behandlung von tumoren | |
| ATE284959T1 (de) | Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| DE60136826D1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
| ATE238792T1 (de) | Verwendung von makroliden zur behandlung von glaukom | |
| DE60306896D1 (de) | Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen | |
| DE60233433D1 (de) | PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN | |
| MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
| ATE457027T1 (de) | Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1319000 Country of ref document: EP |